Novel transcript, antisense to LDLRAD3

Novel transcript, antisense to LDLRAD3 (Ensembl ID: ENSG00000306088) refers to a predicted non-coding RNA gene/transcript that is transcribed in the antisense orientation relative to the LDLRAD3 gene[9]. This entity is annotated as an RNA gene, not a protein-coding gene, and does not encode a protein or function as a therapeutic target like a receptor, enzyme, or transporter. There is no evidence in the literature or gene/protein databases supporting this transcript as a canonical or validated molecular target for drug, diagnostic, or biomarker development. Its function, if any, would likely be related to regulation of LDLRAD3 expression, but there is no published data confirming biological activity, disease relevance, or druggability. Further notes: - The canonical, experimentally validated target is Low-density lipoprotein receptor class A domain-containing 3 (LDLRAD3), a protein receptor involved in Venezuelan equine encephalitis virus entry and certain regulatory functions[1][2][3][5]. - This antisense transcript is not the canonical LDLRAD3 gene (Ensembl: ENSG00000179241), and the term "novel transcript, antisense to LDLRAD3" does not refer to a defined protein or therapeutic target. - Because it is not a protein, not a confirmed regulatory target, and has no established abbreviations or biological roles, it should not be treated as a conventional drug target in structured data sets[9].

Other names

Novel transcript, antisense to LDLRAD3ENSG00000306088